679409-18-8

Basic information

• Product Name: 1-BOC-4-(3-FLUORO-PHENYLAMINO)-PIPERIDINE
• Synonyms: 1-BOC-4-(3-FLUORO-PHENYLAMINO)-PIPERIDINE;tert-Butyl 4-((3-fluorophenyl)aMino)piperidine-1-carboxylate
• CAS NO: 679409-18-8
• Molecular Formula: C₁₆H₂₃FN₂O₂
• Molecular Weight: 294.36
• Mol File: 679409-18-8.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 1-BOC-4-(3-FLUORO-PHENYLAMINO)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(3-FLUORO-PHENYLAMINO)-PIPERIDINE(679409-18-8)
• EPA Substance Registry System: 1-BOC-4-(3-FLUORO-PHENYLAMINO)-PIPERIDINE(679409-18-8)

Safety Data

• Hazardous Substances Data: 679409-18-8(Hazardous Substances Data)

Usage

General Description

1-BOC-4-(3-FLUORO-PHENYLAMINO)-PIPERIDINE is a type of synthetic compound used in the pharmaceutical industry and in scientific research. The structural formula for this complex chemical includes an element of fluorine, which is often used to enhance the bioactivity of pharmaceuticals. It also features a piperidine backbone, characteristic of many pharmaceuticals. The BOC, or tert-butoxycarbonyl group, is used to protect the amine groups during synthesis. Though specific applications for this compound may vary, it is generally geared towards various medical and scientific purposes within lab-based or manufacturing settings.

Upstream product

• 372-19-0 meta-fluoroaniline 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1150111-53-7 1,1-dimethylethyl 4-{(3-fluorophenyl)[({1-[(methyloxy)methyl]-1H-indazol-6-yl}amino)carbonyl]amino}-1-piperidinecarboxylate 
• 1259931-68-4 C₂₅H₂₉FN₄O₃ 
• 1344734-71-9 C₂₃H₂₅F₂N₅O₃ 
• 1344734-65-1 C₂₃H₂₈BrFN₄O₃ 
• 1344734-62-8 C₂₄H₂₈FN₅O₃ 
• 1344734-75-3 C₃₂H₃₃F₂N₇O₅S 
• 1344734-74-2 C₃₃H₃₆FN₇O₅S 
• 1344734-73-1 C₃₃H₃₆FN₇O₅S 

Relevant articles and documents

Synthesis and antimalarial activity of 1,4-disubstituted piperidine derivatives

In order to prepare, at low cost, new compounds active against Plasmodium falciparum, and with a less side-effects, we have designed and synthesized a library of 1,4-disubstituted piperidine derivatives from 4-aminopiperidine derivatives 6. The resulting compound library has been evaluated against chloroquine-sensitive (3D7) and chloroquine-resistant (W2) strains of P. falciparum. The most active molecules—compounds 12d (13.64 nM (3D7)), 13b (4.19 nM (3D7) and 13.30 nM (W2)), and 12a (11.6 nM (W2))—were comparable to chloroquine (22.38 nM (3D7) and 134.12 nM (W2)).

Discovery of novel pyridyl carboxamides as potent CCR5 antagonists and optimization of their pharmacokinetic profile in rats

A novel series of pyridyl carboxamide-based CCR5 inhibitors was designed, synthesized, and demonstrated to be highly potent against HIV-1 infection in both HOS and PBL assays. Attempts to evaluate this series of compounds in a rat PK model revealed its instability in rat plasma. A hypothesis for this liability was proposed, and strategies to overcome this issue were pursued, leading to discovery of highly potent 40 and 41, which featured dramatically improved rat PK profiles. 2011 Elsevier Ltd. All rights reserved.

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acq